Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
09 janv. 2025 10h00 HE
|
Numab Therapeutics AG
CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and...
Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs
23 déc. 2024 08h00 HE
|
Neutrolis, Inc.
CAMBRIDGE, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neutrolis Inc., a clinical stage biotech company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and...
Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors
12 déc. 2024 10h05 HE
|
Invea Therapeutics
GUILFORD, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Invea Therapeutics, Inc. (Invea), a leading biotechnology company developing an artificial intelligence (AI), GenAI, and machine learning (ML)...
GEn1E Lifesciences appoints François Nader, MD as Chair of its Board of Directors
11 déc. 2024 07h01 HE
|
GEn1E Lifesciences Inc.
Dr. Nader, current Independent Board Director at Moderna and Senior Advisor at Blackstone Life Sciences, joins GEn1E Lifesciences board as chair.
Bionical Emas sells EMAS Pharma to Kester Capital following strategic review
09 déc. 2024 02h00 HE
|
Bionical Emas
Bionical Emas, the Early Access Programs and Clinical Trial Supply business, is selling EMAS Pharma to Kester Capital and an incoming executive team.
Kester Capital backs experienced management team in acquiring EMAS Pharma
09 déc. 2024 02h00 HE
|
EMAS Pharma
Kester Capital, alongside a new senior management team, has acquired EMAS Pharma, the clinical development division of Bionical Emas.
Derm-Biome Pharmaceuticals adds Dr. Jerry Tan, internationally renowned expert in acne and acne scarring, to its Scientific Advisory Board
25 nov. 2024 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company developing safe and highly effective topical treatments...
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
05 nov. 2024 07h00 HE
|
ZyVersa Therapeutics
Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
17 oct. 2024 08h07 HE
|
BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
Attovia Therapeutics Appoints Chief Financial Officer
15 oct. 2024 07h30 HE
|
Attovia Therapeutics, Inc.
FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and...